Kender Richard N 4

What Happened
Richard N. Kender, interim Chief Executive Officer and director of Seres Therapeutics (MCRB), was granted a derivative award for 150,000 shares on 2026-03-04. The reported acquisition price is $0.00 and the transaction is recorded as an award/grant (code A). This is a grant of a derivative equity award (options or similar) — not an open-market purchase or sale — so there was no cash exchanged at grant.

Key Details

• Transaction date: 2026-03-04; Form 4 filed 2026-03-06 (timely within the typical 2-business-day window).
• Amount granted: 150,000 shares (derivative award). Reported price: $0.00; reported value: $0 (per filing excerpt).
• Vesting/exercise: Footnote indicates the option vests and becomes exercisable in 36 equal monthly installments (3-year monthly vesting).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A (award/grant); no 10b5-1, tax withholding, or sale reported in the excerpt.

Context
This filing reports a grant of a derivative award (likely stock options) that will vest over time — not an immediate exercise or sale. Such grants are common for executive compensation and align future pay with company performance; they do not represent an immediate cash investment by the insider. No speculative conclusions about intent should be drawn from the grant alone.